

INTRODUCTION .....	XX
STUDY GOALS AND OBJECTIVES.....	XX
REASONS FOR DOING THE STUDY .....	XX
CONTRIBUTION OF THE STUDY AND FOR WHOM .....	XXI
SCOPE OF REPORT .....	XXI
METHODOLOGY .....	XXI
INFORMATION SOURCES.....	XXII
RELATED BCC REPORTS .....	XXII
ANALYST CREDENTIALS.....	XXII
BCC ONLINE SERVICES.....	XXIII
DISCLAIMER .....	XXIII
 SUMMARY.....	 XXIV
<i>SUMMARY TABLE GLOBAL VALUE OF RNA INTERFERENCE</i>	
<i>MARKET BY MARKET SEGMENT, THROUGH 2013 (\$ MILLIONS)</i> .....	XXV
<i>SUMMARY FIGURE GLOBAL VALUE OF RNA INTERFERENCE</i>	
<i>MARKET BY MARKET SEGMENT, 2006-2013 (\$ MILLIONS)</i> .....	XXVI
 OVERVIEW .....	 1
INTRODUCTION .....	1
CONVERGENCE OF POST GENOME TECHNOLOGIES.....	1
<i>TABLE 1 POST GENOME ENABLING TOOLS</i> .....	1
<i>TABLE 2 NEW PARADIGM OF RNA INTERFERENCE</i> .....	2
MARKET POTENTIAL OF RNA INTERFERENCE-BASED	
PRODUCTS .....	3
GLOBAL RNAI MARKET FORECAST .....	3
<i>TABLE 3 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY</i>	
<i>MARKET SEGMENT, THROUGH 2013 (\$ MILLIONS)</i> .....	3
GLOBAL RNAI RESEARCH TOOLS MARKET .....	3
<i>TABLE 4 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH</i>	
<i>TOOLS MARKET BY PRODUCT TYPE, THROUGH 2013</i>	
<i>(\$ MILLIONS)</i> .....	4
<i>TABLE 5 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET,</i>	
<i>BY CLASS, THROUGH 2013 (\$ MILLIONS)</i> .....	5
GROWTH DRIVING FORCES IN RNA INTERFERENCE MARKETS.....	6
<i>TABLE 6 PRIMARY FORCES DRIVING RNA INTERFERENCE</i>	
<i>GROWTH</i> .....	6
RNA INTERFERENCE: BUILDING ON ANTISENSE	
TECHNOLOGIES.....	7
<i>TABLE 7 KEY ANTISENSE CONTRIBUTIONS TO RNA</i>	
<i>INTERFERENCE</i> .....	8
APPLICATIONS OF RNA INTERFERENCE .....	8
RNA INTERFERENCE AS A GENE KNOCKDOWN	
TECHNOLOGY.....	9

RNA INTERFERENCE AS A BIOMARKER.....	9
RNA INTERFERENCE IN THERAPEUTICS.....	9
RNA INTERFERENCE IN AGRICULTURE .....	9
THE RNA INTERFERENCE INDUSTRY .....	10
The RNA Interference Industry (Continued) .....	11
RNA INTERFERENCE TECHNOLOGIES.....	12
INTRODUCTION .....	12
ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION .....	12
<i>FIGURE 1 ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION</i> .....	13
<i>TABLE 8 BASIC STEPS IN PROTEIN PRODUCTION</i> .....	13
RNA INTERFERENCE PROCESS.....	14
<i>FIGURE 2 RNA INTERFERENCE PROCESS</i> .....	15
GENE SILENCING TECHNOLOGIES.....	16
<i>TABLE 9 COMPARISON OF RNA INTERFERENCE AND ANTISENSE</i>	
<i>OLIGO TECHNOLOGIES</i> .....	17
<i>TABLE 10 SHORT INTERFERING, SHORT HAIRPIN, AND MICRO</i>	
<i>RNA VERSUS OLIGO ANTISENSE TECHNOLOGIES</i> .....	18
<i>TABLE 10 (CONTINUED)</i> .....	19
SHORT HAIRPIN RNA .....	19
MICRO RNA.....	19
Introduction .....	19
miRNAs and Cancer .....	20
miRNA Biogenesis.....	21
<i>FIGURE 3 MICRO RNA BIOGENESIS</i> .....	21
SIRNAS.....	22
RNA INTERFERENCE HISTORY .....	23
<i>TABLE 11 RNA INTERFERENCE HISTORY</i> .....	23
<i>TABLE 11 (CONTINUED)</i> .....	24
RNAI: BUILDING ON AN ANTISENSE TECHNOLOGY PLATFORM .....	25
<i>TABLE 12 ANTISENSE TECHNOLOGY PLATFORMS</i> .....	26
APPLICATIONS OF RNA INTERFERENCE.....	27
<i>TABLE 13 NEAR TERM RNA INTERFERENCE COMMERCIAL</i>	
<i>APPLICATIONS</i> .....	27
SIRNA TECHNOLOGY .....	28
SIRNA PRODUCTION TECHNOLOGIES .....	28
<i>TABLE 14 COMPARISON OF METHODS FOR PRODUCING SHORT</i>	
<i>INTERFERING RNA</i> .....	28
<i>TABLE 14 (CONTINUED)</i> .....	29
Chemical Synthesis .....	29
<i>In vitro</i> Transcription .....	30
<i>In vitro</i> Transcription Followed by Dicer Digestion (Dicer	
Substrate siRNA) .....	31
PCR Expression Cassettes .....	31
Plasmid or Viral Vector Expression.....	32

SHORT INTERFERING RNA LIBRARIES.....	33
RNA INTERFERENCE RESEARCH TOOL PRODUCTS.....	34
<i>FIGURE 4 RNA INTERFERENCE RESEARCH TOOLS PRODUCTS.....</i>	<i>34</i>
SIRNA EFFECTORS .....	35
<i>TABLE 15 COMPARISON OF SYNTHETIC AND PLASMID SHORT</i>	
<i>INTERFERING RNA PRODUCTION TECHNOLOGIES.....</i>	<i>35</i>
<i>TABLE 15 (CONTINUED).....</i>	<i>36</i>
SHORT INTERFERING RNA EFFECTOR MOLECULE	
DESIGN.....	36
Short Interfering RNA Effector ... (Continued) .....	37
siRNA Design Goals .....	38
Off-target Effects .....	38
<i>TABLE 16 TYPES OF OFF-TARGET EFFECTS.....</i>	<i>39</i>
INDUSTRY STANDARDS FOR SHORT INTERFERING RNA	
PERFORMANCE .....	40
POOLED SHORT INTERFERING RNAS .....	40
DELIVERY .....	41
DETECTION .....	41
mRNA Detection.....	42
<i>TABLE 17 RNA DETECTION TECHNOLOGIES.....</i>	<i>42</i>
Protein Detection.....	43
Functional Assays.....	43
Other Detection Strategies.....	44
SHORT INTERFERING RNA LENGTH RATIONALE.....	44
RNA INTERFERENCE IN RESEARCH TOOLS MARKETS.....	45
POST-GENOME ERA RESEARCH TRENDS .....	45
<i>TABLE 18 POST GENOME RESEARCH LANDSCAPE.....</i>	<i>45</i>
APPLICATIONS OF RNA INTERFERENCE AS A RESEARCH TOOL.....	46
<i>TABLE 19 RNA INTERFERENCE APPLICATIONS AS A RESEARCH</i>	
<i>TOOL.....</i>	<i>46</i>
GENE KNOCKDOWN .....	46
PATHWAY ANALYSIS .....	47
DRUG TARGET DISCOVERY AND VALIDATION .....	47
<i>TABLE 20 RNA INTERFERENCE APPROACH TO IDENTIFY TIGHT</i>	
<i>JUNCTION PROTEIN TARGETS.....</i>	<i>48</i>
FUNCTIONAL GENOMICS EXPERIMENTAL WORKFLOW.....	49
<i>TABLE 21 FUNCTIONAL GENOMICS RESEARCH WORKFLOW AND</i>	
<i>RELATED RNA INTERFERENCE PRODUCTS.....</i>	<i>49</i>
MICRO RNA FUNCTIONAL ANALYSIS EXPERIMENTAL	
WORKFLOW.....	50
TECHNOLOGY NEEDS.....	50
<i>TABLE 22 TECHNOLOGY NEEDS FOR RNA INTERFERENCE AS A</i>	
<i>RESEARCH TOOL.....</i>	<i>51</i>

RNA INTERFERENCE IN DIAGNOSTICS .....	52
INTRODUCTION .....	52
<i>TABLE 23 BIOMARKER COMPARISON</i> .....	52
CORE SKILLS FOR MIRNA DIAGNOSTICS.....	53
<i>TABLE 24 ENABLING TECHNOLOGIES FOR MICRO RNA</i>	
<i>DIAGNOSTICS DEVELOPMENT</i> .....	53
<i>IN VITRO</i> DIAGNOSTICS DEVELOPMENT STAGES .....	54
<i>TABLE 25 IN VITRO DIAGNOSTICS DEVELOPMENT PHASES</i> .....	54
Biomarker Discovery .....	55
Assay Development .....	55
Clinical Validation.....	56
Regulatory Review and Approval .....	56
RNAI DIAGNOSTICS PIPELINE.....	56
<i>TABLE 26 RNA INTERFERENCE DIAGNOSTICS PIPELINE</i> .....	57
RNAi Diagnostics Pipeline (Continued) .....	58
RNAi Diagnostics Pipeline (Continued) .....	59
 RNA INTERFERENCE IN AGRICULTURE.....	60
MARKET DRIVING FORCES .....	60
<i>TABLE 27 DRIVING FORCES FOR RNA INTERFERENCE-BASED</i>	
<i>CROP PROTECTION</i> .....	60
RNA INTERFERENCE-BASED INSECTICIDES .....	61
RNA INTERFERENCE-BASED CROP TRAITS.....	61
DEVELOPMENT OF A GENETICALLY MODIFIED SEED.....	62
<i>TABLE 28 GENETICALLY MODIFIED SEED DEVELOPMENT</i>	
<i>PROCESS</i> .....	62
RNA INTERFERENCE ADVANTAGES IN AGRICULTURE	
APPLICATIONS .....	63
 RNA INTERFERENCE THERAPEUTICS TECHNOLOGIES.....	64
INTRODUCTION .....	64
<i>FIGURE 5 DRUG PLATFORMS</i> .....	65
RNA INTERFERENCE THERAPY COMPARATIVE ADVANTAGES .....	65
<i>TABLE 29 RNA INTERFERENCE THERAPY: COMPARATIVE</i>	
<i>ADVANTAGES</i> .....	66
<i>FIGURE 6 RNA INTERFERENCE IN DRUG DISCOVERY AND</i>	
<i>DEVELOPMENT</i> .....	67
RNA INTERFERENCE THERAPEUTIC APPROACHES .....	68
<i>TABLE 30 RNA INTERFERENCE THERAPEUTIC APPROACHES</i> .....	69
SIRNA DRUG DEVELOPMENT PROCESS.....	69
<i>FIGURE 7 SHORT INTERFERING RNA DRUG DEVELOPMENT</i>	
<i>PROCESS</i> .....	70
RNA INTERFERENCE DELIVERY TECHNOLOGIES .....	71
<i>FIGURE 8 RNA INTERFERENCE: LOCAL DELIVERY APPROACHES</i> .....	72

<i>FIGURE 9 RNA INTERFERENCE SYSTEMIC DELIVERY</i>	
<i>APPROACHES</i> .....	73
<i>TABLE 31 IN-VIVO VIRAL VECTOR TECHNOLOGIES COMPARED</i> .....	74
<i>TABLE 31 (CONTINUED)</i> .....	75
<i>TABLE 32 RNA INTERFERENCE DELIVERY TECHNOLOGY</i>	
<i>PLATFORMS IN CLINICAL TRIALS</i> .....	76
KEY DEVELOPMENT NEEDS FOR RNA INTERFERENCE	
THERAPEUTICS .....	77
<i>TABLE 33 RNA INTERFERENCE THERAPEUTICS KEY</i>	
<i>DEVELOPMENT NEEDS</i> .....	77
KEY DEVELOPMENT NEEDS ...(CONTINUED) .....	78
MICRO RNA THERAPEUTICS.....	79
RNA INTERFERENCE THERAPEUTICS PIPELINE .....	80
ANTISENSE BACKGROUND.....	80
<i>TABLE 34 ANTISENSE OLIGO CLINICAL PIPELINE STATUS</i> .....	80
<i>TABLE 34 (CONTINUED)</i> .....	81
RNA INTERFERENCE PIPELINE OVERVIEW.....	81
<i>TABLE 35 RNA INTERFERENCE DEVELOPMENT AND CLINICAL</i> .....	81
<i>PIPELINE SUMMARY</i> .....	81
<i>TABLE 36 DISEASES TARGETED BY RNA INTERFERENCE</i>	
<i>THERAPEUTICS</i> .....	82
<i>TABLE 36 (CONTINUED)</i> .....	83
PRE-CLINICAL RNAI PIPELINE .....	84
<i>TABLE 37 RNA INTERFERENCE THERAPY PRE-CLINICAL</i>	
<i>PIPELINE STATUS</i> .....	84
<i>TABLE 37 (CONTINUED)</i> .....	85
<i>TABLE 37 (CONTINUED)</i> .....	86
Alynlam.....	86
AlphaGen .....	87
Benitec.....	87
Calando .....	88
Genable .....	88
Genesis.....	88
Genecare .....	88
Intradigm .....	89
Nastech .....	89
Nucleonics .....	89
Opko Health.....	90
Protiva.....	91
Quark Pharmaceuticals.....	92
Rosetta Genomics .....	92
Santaris.....	92
Silence Therapeutics .....	93
SirnaSense .....	93

Tacare.....	93
Targeted Genetics.....	94
TransGenex.....	94
RNAI CLINICAL PIPELINE.....	94
<i>TABLE 38 RNA INTERFERENCE THERAPY CLINICAL PIPELINE</i>	
<i>STATUS</i> .....	95
Allergan.....	95
Alylam.....	95
Antigen Express.....	96
Benitec.....	96
Nucleonics .....	97
Opko Health.....	98
Quark Pharmaceuticals.....	98
Pfizer .....	99
RNA INTERFERENCE THERAPEUTICS DISEASE OVERVIEWS .....	99
INTRODUCTION.....	99
OPHTHALMIC DISEASES .....	100
Introduction .....	100
Epidemiology.....	100
<i>TABLE 39 AMD GROWTH DRIVING FORCES</i> .....	101
Existing and Emerging Therapies .....	101
<i>TABLE 40 CLINICAL DEVELOPMENT PIPELINE FOR AMD</i> .....	102
Existing and Emerging ... (Continued).....	103
Challenges for Existing and Emerging Therapies .....	104
<i>TABLE 41 COMPARISON OF BEVASIRANIB, LUCENTIS AND</i>	
<i>MACUGEN</i> .....	105
RESPIRATORY SYNCYTIAL VIRUS.....	106
Epidemiology.....	106
Existing and Emerging Therapies .....	106
<i>TABLE 42 RSV DRUG PIPELINE</i> .....	106
<i>TABLE 42 (CONTINUED)</i> .....	107
Treatment Segment.....	107
Prevention Segment .....	108
Challenges for Existing and Emerging Therapies .....	108
INFLUENZA .....	109
Epidemiology.....	109
Existing and Emerging Therapies .....	110
Limitations of Existing and Emerging Therapies.....	110
HEPATITIS C VIRUS (HCV) .....	111
Epidemiology.....	111
Existing and Emerging Therapies .....	111
Limitations of Existing and Emerging Therapies.....	112
HEPATITIS B VIRUS (HBV) .....	112
Epidemiology.....	112

Existing and Emerging Therapies .....	112
Limitations of Existing and Emerging Therapies.....	113
ACUTE RENAL FAILURE.....	114
Epidemiology.....	114
Existing Therapies.....	115
Limitations of Existing Therapies .....	115
ONCOLOGY .....	115
HYPERLIPIDEMIA .....	116
RNA INTERFERENCE MARKETS .....	117
GROWTH DRIVING FORCES.....	117
<i>TABLE 43 PRIMARY FORCES DRIVING RNA INTERFERENCE</i>	
<i>GROWTH</i> .....	117
FUNDING FOR LIFE SCIENCE RESEARCH .....	117
NEW DISCOVERIES IN GENOMICS AND	
NANOTECHNOLOGIES.....	118
NEED FOR EFFICIENT DRUG DISCOVERY AND	
DEVELOPMENT .....	118
NEED FOR PLATFORMS THAT CAN ACCESS	
‘UNDRUGGABLE’ TARGETS.....	119
GROWTH IN PERSONALIZED MEDICINES .....	119
NEED FOR ENVIRONMENTALLY FRIENDLY	
AGROCHEMICALS .....	119
RNA INTERFERENCE OVERALL MARKET .....	120
<i>TABLE 44 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY</i>	
<i>MARKET SEGMENT, THROUGH 2013 (\$ MILLIONS)</i> .....	120
<i>TABLE 45 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY</i>	
<i>GEOGRAPHY, THROUGH 2013 (\$ MILLIONS)</i> .....	121
RNAI RESEARCH TOOLS MARKET .....	121
<i>TABLE 46 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH</i>	
<i>TOOLS MARKET BY PRODUCT TYPE, THROUGH 2013</i>	
<i>(\$ MILLIONS)</i> .....	122
<i>TABLE 47 GLOBAL VALUE OF SYNTHETIC SHORT INTERFERING</i>	
<i>RNA MARKET BY PRODUCT TYPE, THROUGH 2013 (\$ MILLIONS)</i> ....	123
<i>TABLE 48 GLOBAL VALUE OF RNA INTERFERENCE DETECTION</i>	
<i>REAGENTS/KITS, BY TECHNOLOGY, THROUGH 2013</i>	
<i>(\$ MILLIONS)</i> .....	124
<i>TABLE 49 GLOBAL VALUE OF RNA INTERFERENCE DETECTION</i>	
<i>REAGENTS/KITS, BY BIOLOGICAL TARGET, THROUGH 2013</i>	
<i>(\$ MILLIONS)</i> .....	125
<i>TABLE 50 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH</i>	
<i>TOOLS, BY GEOGRAPHY, THROUGH 2013 (\$ MILLIONS)</i> .....	126
RNAI DIAGNOSTICS MARKET .....	126
<i>TABLE 51 GLOBAL VALUE OF RNA INTERFERENCE DIAGNOSTICS</i>	
<i>MARKET, BY TYPE, THROUGH 2013 (\$ MILLIONS)</i> .....	127

<i>TABLE 52 GLOBAL VALUE OF RNA INTERFERENCE DIAGNOSTICS MARKET, BY INDICATION, THROUGH 2013 (\$ MILLIONS)</i> .....	128
<i>TABLE 53 GLOBAL VALUE OF RNA INTERFERENCE DIAGNOSTICS MARKET, BY GEOGRAPHY, THROUGH 2013 (\$ MILLIONS)</i> .....	129
RNA INTERFERENCE THERAPEUTICS MARKET .....	129
<i>TABLE 54 RNA INTERFERENCE GLOBAL AVAILABLE DRUG MARKET, THROUGH 2013 (\$ MILLIONS)</i> .....	130
<i>TABLE 55 RNA INTERFERENCE THERAPEUTICS CLINICAL AND LATE STAGE PRECLINICAL PROJECTS AND MARKET ASSUMPTIONS</i> .....	131
RNA INTERFERENCE THERAPEUTICS ... (CONTINUED).....	132
<i>TABLE 56 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET, BY CLASS, THROUGH 2013 (\$ MILLIONS)</i> .....	133
<i>TABLE 57 GLOBAL VALUE OF RNA INTERFERENCE OPHTHALMIC DRUG MARKET, THROUGH 2013 (\$ MILLIONS)</i> .....	134
<i>TABLE 58 GLOBAL VALUE OF RNA INTERFERENCE VIRAL DISEASE DRUG MARKET BY INDICATION, THROUGH 2013 (\$ MILLIONS)</i> .....	135
RNA INTERFERENCE THERAPEUTICS ... (CONTINUED).....	136
RNA INTERFERENCE THERAPEUTICS ... (CONTINUED).....	136
<i>TABLE 59 GLOBAL VALUE OF RNA INTERFERENCE CANCER DRUG MARKET BY INDICATION, THROUGH 2013 (\$ MILLIONS)</i> .....	137
<i>TABLE 60 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET BY GEOGRAPHY, THROUGH 2013 (\$ MILLIONS)</i> .....	137
<i>TABLE 61 GLOBAL VALUE OF OVERALL RNA INTERFERENCE DRUG MARKET BY DELIVERY TECHNOLOGY, THROUGH 2013 (\$ MILLIONS)</i> .....	138
RNA INTERFERENCE THERAPEUTICS ... (CONTINUED).....	139
RNA INTERFERENCE AGRICULTURAL MARKETS.....	139
<i>TABLE 62 GLOBAL VALUE OF RNA INTERFERENCE AGRICULTURAL MARKET, BY PRODUCT, THROUGH 2013 (\$ MILLIONS)</i> .....	139
<i>TABLE 63 GLOBAL VALUE OF RNA INTERFERENCE AGRICULTURAL MARKET, BY GEOGRAPHY, THROUGH 2013 (\$ MILLIONS)</i> .....	140
RNA INTERFERENCE COMPETITOR LANDSCAPE.....	141
INTRODUCTION .....	141
R&D TOOLS.....	141
DIAGNOSTICS .....	142
<i>TABLE 64 RNA INTERFERENCE DIAGNOSTICS COMPANY RELATIVE STRATEGIC POSITION</i> .....	142
Diagnostics (Continued).....	143
THERAPEUTICS .....	144
Company Strategic Positions .....	144



<i>TABLE 65 RNA INTERFERENCE THERAPEUTIC COMPANY</i>	
<i>RELATIVE STRATEGIC POSITION</i> .....	144
<i>TABLE 65 (CONTINUED)</i> .....	145
<i>TABLE 66 THERAPEUTIC RNA INTERFERENCE COMPETITOR</i>	
<i>STRATEGIC MARKET POSITION</i> .....	146
Big Pharma Strategic Alliances with RNAi Companies.....	147
<i>TABLE 67 BIG PHARMA RNA INTERFERENCE STRATEGIC</i>	
<i>ALLIANCES</i> .....	147
<i>TABLE 67 (CONTINUED)</i> .....	148
Big Pharma Strategic ...(Continued).....	149
RNAI PATENTS.....	150
BASIC RNAI PATENT TYPES.....	150
<i>TABLE 68 BASIC RNA INTERFERENCE PATENT TYPES</i> .....	150
MICRO RNA PATENTS.....	151
<i>TABLE 69 KEY STEPS FOR PATENTING MICRO RNA</i> .....	151
RNA INTERFERENCE PATENT LANDSCAPE.....	152
<i>TABLE 70 RNA INTERFERENCE CORE PATENT STRATEGIES</i> .....	152
RNA INTERFERENCE CORE PATENT ESTATES.....	153
<i>TABLE 71 RNA INTERFERENCE CORE PATENT ESTATES</i> .....	154
<i>TABLE 71 (CONTINUED)</i> .....	155
MELLO & FIRE, ISSUED JANUARY 2004.....	155
CROOKE (ISSUED 1999 AND 2000).....	156
TUSCHL I (APPLICATION PENDING) AND TUSCHL II	
(ISSUED JULY 2006) PATENT ESTATES.....	156
<i>TABLE 72 TUSCHL I AND TUSCHL II CLAIMS</i> .....	157
KREUTZER-LIMMER (K-L) PATENT (ISSUED 2002).....	158
<i>TABLE 73 COMPARISON OF TUSCHL AND K-L PATENT ESTATES</i> .....	158
BENITEC (ISSUED JUNE 2003, PULLED FOR RE-	
EXAMINATION).....	159
MICRO RNA PATENTS.....	159
<i>TABLE 74 ACCESS TO VALIDATED HUMAN MICRO RNA</i> .....	160
APPROACHES FOR WORKING AROUND THE CORE PATENTS.....	160
RNA INTERFERENCE PATENT LITIGATION STATUS.....	161
<i>TABLE 75 RECENT RNA INTERFERENCE IP COURT ACTIVITY</i> .....	162
INTELLECTUAL PROPERTY STRATEGIES OF SELECTED RNA	
INTERFERENCE COMPANIES.....	163
ALNYLAM.....	163
<i>TABLE 76 RECENT ALNYLAM PATENT ACTIVITY</i> .....	164
SILENCE THERAPEUTICS.....	165
BENITEC.....	165
ISIS PHARMACEUTICALS.....	166
ROSETTA GENOMICS.....	166
Rosetta Genomics (Continued).....	167

COMPANY PROFILES .....	168
454 LIFE SCIENCES .....	168
ACTIGENICS S.A. ....	168
AGILENT TECHNOLOGIES, INC. ....	169
ALLERGAN, INC. ....	170
ALNYLAM PHARMACEUTICALS .....	171
<i>TABLE 77 ALNYLAM SELECTED COMPANY DEALS</i> .....	172
<i>TABLE 78 ALNYLAM IP STRATEGY</i> .....	172
<i>TABLE 79 ALNYLAM KEY COLLABORATIONS</i> .....	173
<i>TABLE 79 (CONTINUED)</i> .....	174
ALNYLAM PHARMACEUTICALS (CONTINUED) .....	175
<i>TABLE 80 ALNYLAM PRODUCT PIPELINE SUMMARY</i> .....	176
ALPHAGEN COMPANY LIMITED .....	177
AMAXA AG .....	178
ANTIGEN EXPRESS, INC. ....	179
APPLIED BIOSYSTEMS .....	180
ASTRAZENECA.....	180
ASURAGEN, INC. ....	181
B-BRIDGE INTERNATIONAL INC. ....	182
BENITEC LIMITED .....	183
BIOCAT GMBH .....	184
BIOCHAIN INSTITUTE INC. ....	185
BIOGNOSTIK GMBH.....	185
BIONEER CORPORATION .....	185
BIO-RAD LABORATORIES .....	186
CALANDO PHARMACEUTICALS INC. ....	186
<i>TABLE 81 CALANDO LICENSES</i> .....	187
CEPHEID .....	187
CEQUENT PHARMACEUTICALS, INC. ....	188
CENIX BIOSCIENCE GMBH .....	189
CLINICAL DATA INC. ....	189
CLONTECH .....	190
COMBIMATRIX CORPORATION .....	190
DEVGEN NV .....	191
DEVGEN NV (CONTINUED) .....	192
DHARMACON INC. ....	193
DNAVISION SA .....	194
EUROGENTEC S.A. ....	195
EXIQON A/S.....	195
FEBIT BIOTECH GMBH .....	196
F. HOFFMANN-LA ROCHE LTD.....	196
GALAPAGOS NV .....	197
GENABLE TECHNOLOGIES LIMITED .....	198
GENECARE RESEARCH INSTITUTE CO. ....	199

GENECOPOEIA, INC. ....	200
GENEDESIGN, INC.....	200
GENE LINK, INC. ....	200
GENESERVICE LIMITED.....	201
GENOSENSOR CORPORATION .....	201
GENESIS RESEARCH & DEVELOPMENT CORPORATION LIMITED.....	202
GENOMICA S.A.U.....	202
GENOWAY.....	203
GENLANTIS .....	203
GENSCRIPT CORPORATION.....	203
GENTA INC. ....	204
IDERA PHARMACEUTICALS INC. ....	204
IMAGENES GMBH .....	205
IMGENEX CORP.....	205
IMMUTHES THERAPEUTICS LTD.....	205
INTEGRATED DNA TECHNOLOGIES.....	206
INTRADIGM .....	207
INVITROGEN CORPORATION .....	208
INVIVOGEN .....	208
ISIS PHARMACEUTICALS, INC.....	209
LENTIGEN CORPORATION.....	209
MERCK & CO. INC. ....	210
MIRUS BIO CORPORATION .....	210
NASTECH PHARMACEUTICALS.....	211
NASTECH PHARMACEUTICALS (CONTINUED).....	212
NOVOSOM AG.....	213
NUCLEONICS, INC. ....	214
NUCLEONICS, INC. (CONTINUED).....	215
NUCLEIS .....	216
OLIGOENGINE.....	216
OPEN BIOSYSTEMS .....	217
OPKO HEALTH, INC.....	217
ORIGENE TECHNOLOGIES, INC. ....	218
OZ BIOSCIENCES .....	218
PHYTOVATION BV .....	219
POLYPLUS TRANSFECTION SA.....	219
PRONAI THERAPEUTICS, INC. ....	220
PROTIVA BIOTHERAPEUTICS .....	220
PROTIVA BIOTHERAPEUTICS (CONTINUED).....	221
QIAGEN GMBH.....	222
QUARK BIOTECH, INC.....	223
<i>TABLE 82 QUARK DEVELOPMENT PIPELINE .....</i>	<i>223</i>
REGULUS PHARMACEUTICALS.....	224

RNAX GMBH .....	225
ROSETTA GENOMICS, LTD.....	225
ROSETTA GENOMICS, LTD. (CONTINUED) .....	226
THE LEAD DIAGNOSTICS PRODUCTS ARE TUMOR CLASSIFICATION .....	227
Differentiation between Adeno- vs Squamous Cell Cancers that are Poorly Differentiated, Mixed or Pure, On Paraffin Samples.....	227
Differentiate between Lung Cancer and Mesothelioma. ....	227
CUP Classification.....	227
CUP Classification (Continued) .....	228
<i>TABLE 83 ROSETTA GENOMICS STRATEGIC PARTNERSHIPS .....</i>	<i>229</i>
RXI PHARMACEUTICALS.....	230
<i>TABLE 84 RXI PHARMACEUTICALS PATENT POSITION SUMMARY.....</i>	<i>231</i>
SANTARIS PHARMA A/S .....	232
SIGMA ALDRICH.....	233
SILENCE THERAPEUTICS PLC.....	234
SILENCE THERAPEUTICS PLC. (CONTINUED) .....	235
SILENCE THERAPEUTICS PLC. (CONTINUED) .....	236
<i>TABLE 85 SILENCE THERAPEUTICS RNA INTERFERENCE DRUG PIPELINE .....</i>	<i>237</i>
SIRNASENSE .....	238
STARPHARMA HOLDINGS LIMITED .....	238
TACERE THERAPEUTICS, INC.....	239
TACERE THERAPEUTICS, INC. (CONTINUED) .....	240
TACONICARTEMIS GMBH .....	241
TEKMIRA PHARMACEUTICALS CORPORATION.....	242
TOLEROTECH INC. ....	243
TRANSAT.....	243
TRANSGENEX NANABIOTECH .....	244
WELGEN CORPORATION.....	245